



## 90% Colon Cancer Microbes Reduced with ProBion Clinica

Blog

Press Release

90% Colon Cancer Microbes Reduced with ProBion Clinica  
Press Release  
GOTHENBURG, Sweden, Sept. 21, 2017

This study was published in the British Medical Journal (BMJ Open Gastro) July 2017

ProBion Clinica study demonstrates probiotic intervention response by altering colon-cancer-associated microbiota to non-cancer microbiota.

ProBion Innovation Sweden AB (PISA), a research biotechnology start-up, announces the results of a clinical trial, registration number NCT03072641, conducted by the Sahlgrenska Academy at University of Gothenburg, in Gothenburg, Sweden, utilizing ProBion Clinica with PISA's proprietary matrix technology on patients with colon cancer. Findings strongly confirm that the colon-cancer-associated microbial signature was modified due to probiotic intervention, characterized by the enrichment of butyrate-producing bacteria in the intestinal tissue along with a regenerated intestinal microbiome profile closely resembling healthy individuals.

"Colon cancer patients harbor a distinct microbiota signature in the tumor tissue and nearby mucosa," said Dr. Yvonne Wettergren, principal investigator of the study. "The ProBion Clinica regimen resulted in overabundance of the beneficial *Faecalibacterium* and *Clostridiales* spp bacteria in the tumor tissue, non-tumor mucosa, as well as in the fecal microbiota, and intriguingly, colon-cancer-associated bacterial genera such as *Fusobacterium* and *Peptostreptococcus* were significantly reduced."

Colorectal cancer (CRC) is the third most common type of cancer in the USA. China has the highest number of new CRC cases in the Asia-Pacific region. The Asia-Pacific CRC market value alone is expected to surpass \$8 billion by 2025.

"There is a great unmet need for new CRC innovative research and treatment options. We are very excited about the results and we are now taking this concept a step further," said Dr. Victoria Rotter Sopasakis, co-founder and CEO of PISA. "I am pleased to announce the planning of a new trial study, at Sahlgrenska University Hospital, on the effects of ProBion Clinica on patients with premalignant adenomas. Based on the current results, we hypothesize that some form of probiotic intervention could effectively prevent colon tumor development in this patient group."

"Many diseases are directly associated with a dysfunctional gut microbiota. Probiotics have a huge potential to improve these conditions and/or improve the efficacy of traditional treatments already in use," added Dr. Lennart Cedgård, co-founder of PISA and inventor of the ProBion matrix formulation. "However, in order to test and evaluate this, it is absolutely imperative to create a formulation that delivers viable, functional, and safe probiotic bacteria to the correct location of the gut. The ProBion matrix elegantly meets all these criteria and the current results could be the start of a paradigm shift."

使用ProBion Clinica減少90%結腸癌微生物  
新聞稿  
瑞典哥德堡，2017年9月21日

該研究發表於2017年7月的英國醫學雜誌 (BMJ Open Gastro)

ProBion Clinica研究通過將結腸癌相關微生物群改變為非癌症微生物群來證明益生菌干預反應。

ProBion Innovation Sweden AB (PISA) 是一家研究生物技術初創公司，宣布由瑞典哥德堡哥德堡大學Sahlgrenska學院進行的臨床試驗結果，註冊號為NCT03072641，利用ProBion Clinica和PISA的專有矩陣技術對結腸癌患者。研究結果強烈證實，由於益生菌干預，結腸癌相關微生物特徵被修改，其特徵在於腸組織中產生丁酸鹽的細菌的富集以及與健康個體非常相似的再生腸微生物組特徵。

"結腸癌患者在腫瘤組織和附近的粘膜中具有明顯的微生物特徵，"該研究的首席研究員Yvonne Wettergren博士說。"ProBion Clinica方案導致腫瘤組織，非腫瘤粘膜以及糞便微生物群中有益的*Faecalibacterium*和*Clostridiales* spp細菌過多，而有趣的是，結腸癌相關的細菌屬如梭桿菌和消化鏈球菌是顯著減少。"

結腸直腸癌 (CRC) 是美國第三種最常見的癌症。中國在亞太地區的新CRC病例數量最多。到2025年，亞太地區的CRC市場價值預計將超過80億美元。

"對於新的CRC創新研究和治療方案存在著巨大的未滿足需求。我們對結果感到非常興奮，我們現在將這一概念更進一步，"PISA聯合創始人兼首席執行官Victoria Rotter Sopasakis博士說。"我很高興地宣布計劃在Sahlgrenska大學醫院進行一項新的試驗研究，探討ProBion Clinica對癌前期腺瘤患者的影響。根據目前的結果，我們假設某種形式的益生菌干預可以有效預防結腸腫瘤該患者群體的發展。"

"許多疾病與功能失調的腸道微生物群直接相關。益生菌具有改善這些病症的巨大潛力和/或提高已經使用的傳統療法的療效，"PISA的聯合創始人兼發明者Lennart Cedgård補充道。ProBion基質配方。"然而，為了測試和評估這一點，絕對必須創建一種配方，將可行的，功能性的，安全的益生菌提供到腸道的正確位置。ProBion矩陣優雅地滿足所有這些標準，目前的結果可能成為範式轉變的開始。"

Sahlgrenska大學醫院的開創性研究是與杜邦營養與健康 (美國)，杜邦全球健康與營養科學 (芬蘭)，哥德堡大學Sahlgrenska學院 (瑞典) 和瓦薩醫學 (瑞典) 合作完成的。

有關ProBion Innovation Sweden AB (PISA)，Sahlgrenska大學醫院研究，ProBion Clinica或其他服務的更多信息，請訪問 [www.probioninnovation.com](http://www.probioninnovation.com)。